The effect of intravenous interleukin-2 on brain water content

Authors:
  • NPNicholas J. Patronas
    Nicholas J. Patronas
  • SRSteven A. Rosenberg
    Steven A. Rosenberg
  • JAJoseph T. Alexander
    Joseph T. Alexander
  • JFJoseph Frank
    Joseph Frank
  • DSDouglas J. Schwartzentruber
    Douglas J. Schwartzentruber
  • JRJoshua T. Rubin
    Joshua T. Rubin
  • DBDavid Barba
    David Barba
  • EOEdward H. Oldfield
    Edward H. Oldfield

Abstract
✓ Parenteral treatment with interleukin-2 (IL-2) is effective against certain advanced cancers outside the central nervous system. Prior to commencement of Phase II trials in patients with brain tumors, the neurological and neuroradiological features of 10 patients treated with intravenous administration of repeated doses of IL-2 were studied. Three patients had malignant gliomas, and seven patients had extracranial cancer without evidence of intracranial metastasis. All were treated with intravenous doses of 105 U/kg three times daily for up to 5 days. The patients with gliomas received cranial computerized axial tomography (CT) scans before IL-2 therapy was initiated and during the later stages of treatment. The patients with extracranial cancer under-went T2-weighted magnetic resonance (MR) imaging before and later during therapy. After two to 11 doses of IL-2, the patients with gliomas had marked neurological deterioration that was associated with a mild to marked increase in peritumoral edema and mas...

This publication has 15 references indexed in Scilit: